Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors

This study introduced a non-invasive, three-step diagnostic algorithm for alopecia that combines clinical and trichoscopic features to accurately identify alopecia subtypes, potentially reducing reliance on invasive histopathology.

This study found that patients with alopecia areata had higher systemic inflammation markers compared to healthy controls, and these markers were associated with a greater risk of severe disease.

This study found that the systemic immune-inflammation index (SII) can be used as a cost-effective marker to assess the severity and treatment response in patients with alopecia areata.

This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.

This study reviewed recent theories on alopecia areata's pathogenesis, highlighting its autoimmune nature due to immune privilege disruption in hair follicles, and noted current treatments have limited efficacy with high relapse rates, underscoring the need for further research into its mechanisms for better therapies.

This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.

In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.